Keywords
How to Cite
Abstract
Ushbu maqolada homiladorlikning kechki toksikozlari, nefropatiya, preeklampsiya va eklampsiya holatlarida homilador ayollarni parvarish qilishning klinik, profilaktik va hamshiralik jihatlari tahlil qilindi. Mavzuning dolzarbligi shundaki, homiladorlikdagi gipertenziv buzilishlar ona va homila hayoti uchun xavfli asoratlar — buyrak yetishmovchiligi, HELLP sindromi, miya shishi, yo‘ldoshning muddatidan oldin ko‘chishi, homila o‘sishining cheklanishi va perinatal o‘lim xavfini oshiradi. Tadqiqotda xalqaro klinik tavsiyalar, ilmiy maqolalar va amaliy parvarish tamoyillari tahlil qilindi. Natijalar shuni ko‘rsatadiki, erta aniqlash, arterial bosimni muntazam nazorat qilish, proteinuriyani baholash, shishlar, nevrologik belgilar, diurez, laborator ko‘rsatkichlar va homila holatini kuzatish preeklampsiya va eklampsiya asoratlarini kamaytirishda muhim o‘rin tutadi. Maqolada shuningdek, og‘ir holatlarda shoshilinch yordam, xavfsiz muhit yaratish, tutqanoq vaqtida nafas yo‘llarini himoya qilish, dori vositalarini shifokor ko‘rsatmasi asosida qo‘llash va tug‘ruqdan keyingi monitoringning ahamiyati yoritildi.
References
1. Homilador ayollar orasida preeklampsiya va eklampsiya xavf belgilari bo‘yicha tushuntirish ishlari kuchaytirilishi lozim.
2. Birlamchi tibbiy bo‘g‘inda arterial bosim va proteinuriyani erta aniqlash tizimi muntazam yo‘lga qo‘yilishi kerak.
3. Akusherka va hamshiralar uchun kechki toksikozlarda shoshilinch yordam algoritmlari bo‘yicha amaliy treninglar o‘tkazilishi maqsadga muvofiq.
4. Tug‘ruqdan keyingi davrda preeklampsiya bilan og‘rigan ayollar uchun alohida monitoring rejasi tuzilishi zarur.
5. Tibbiy hujjatlarda arterial bosim, diurez, laborator natijalar va homila holatini qayd etish intizomi kuchaytirilishi kerak.
Foydalanilgan adabiyotlar:
1. World Health Organization. Pre-eclampsia. Fact sheet. Geneva: WHO; 2025.
2. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO; 2011.
3. World Health Organization. WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia. Geneva: WHO; 2021.
4. World Health Organization. WHO recommendation: Calcium supplementation during pregnancy for prevention of pre-eclampsia and its complications. Geneva: WHO; 2018.
5. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. NICE Guideline NG133. London: NICE; 2019.
6. American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstetrics & Gynecology. 2020;135(6):e237–e260. doi:10.1097/AOG.0000000000003891.
7. Magee L.A., Brown M.A., Hall D.R., et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis and management recommendations for international practice. Pregnancy Hypertension. 2022;27:148–169. doi:10.1016/j.preghy.2021.09.008.
8. Brown M.A., Magee L.A., Kenny L.C., et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension. 2018;72(1):24–43. doi:10.1161/HYPERTENSIONAHA.117.10803.
9. Steegers E.A., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. The Lancet. 2010;376(9741):631–644. doi:10.1016/S0140-6736(10)60279-6.
10. Sharma D.D., Chandnani K., et al. The Management of Preeclampsia: A Comprehensive Review. Cureus. 2024.
11. Magley M., Hinson M.R. Eclampsia. StatPearls Publishing; 2024.
12. Cunningham F.G., Leveno K.J., Bloom S.L., et al. Williams Obstetrics. 26th ed. New York: McGraw-Hill Education; 2022.